Cargando…
Tumor microenvironment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing
BACKGROUND: Immunotherapy has revolutionized cancer treatment, but most patients are refractory to immunotherapy or acquire resistance, with the underlying mechanisms remaining to be explored. METHODS: We characterized the transcriptomes of ~92,000 single cells from 3 pre-treatment and 12 post-treat...
Autores principales: | Hu, Junjie, Zhang, Lele, Xia, Haoran, Yan, Yilv, Zhu, Xinsheng, Sun, Fenghuan, Sun, Liangdong, Li, Shuangyi, Li, Dianke, Wang, Jin, Han, Ya, Zhang, Jing, Bian, Dongliang, Yu, Huansha, Chen, Yan, Fan, Pengyu, Ma, Qiang, Jiang, Gening, Wang, Chenfei, Zhang, Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985263/ https://www.ncbi.nlm.nih.gov/pubmed/36869384 http://dx.doi.org/10.1186/s13073-023-01164-9 |
Ejemplares similares
-
Comparative profiling of single-cell transcriptome reveals heterogeneity of tumor microenvironment between solid and acinar lung adenocarcinoma
por: Li, Dianke, et al.
Publicado: (2022) -
Identification of an Individualized Metabolism Prognostic Signature and Related Therapy Regimens in Early Stage Lung Adenocarcinoma
por: Hu, Junjie, et al.
Publicado: (2021) -
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
por: Bian, Dongliang, et al.
Publicado: (2023) -
Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial
por: Zhu, Xinsheng, et al.
Publicado: (2022) -
Neoadjuvant immunotherapy combined with chemotherapy for local advanced non-small cell lung cancer: a case report
por: Yang, Jie, et al.
Publicado: (2021)